
|Articles|October 1, 2012
SCC prevention is real target in treating actinic keratoses
Options for topical treatment of actinic keratoses (AKs) are increasing, but in choosing a management approach, dermatologists should keep in mind that AKs are a premalignant condition, and the ultimate goal of therapy is prevention of squamous cell carcinoma (SCC). Field treatment is the key to managing the entire disease, says Neal Bhatia, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitors Show Comparable Safety to TNF Antagonists
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5


















